title: [Cryoablation for prostate cancer induces tumor-specific immune response].
abstract: OBJECTIVE
  To assess the anti-tumor immune response to percutaneous cryoablation in patients with local prostate cancer.
  
  
  METHODS
  We treated 10 patients with local prostate cancer by percutaneous cryoablation, collected the blood samples before and 2 weeks after the treatment and isolated peripheral blood mononuclear cells (PBMCs). Protein lysates were made by biopsy from autologous prostate cancer or non-cancer tissues. The levels of serum TNF-alpha, IFN-gamma, IL4 and IL-10 were determined by enzyme-linked immunosorbent assay (ELISA) and the Th1/Th2 ratio was calculated by the IFN-gamma/IL-4 ratio. The number of IFN-gamma + T cells under the stimulation of different protein lysates was counted by enzyme link immunol spot (ELISPOT). And the cytolytic activity of cytotoxic T lymphocytes (CTL) was detected by LDH assay.
  
  
  RESULTS
  Compared with pre-treatment, the levels of TNF-alpha and IFN-gamma, the Th1/ Th2 ratio and the number of IFN-gamma + T cells induced by tumor protein lysates in PBMCs were increased significantly after cryosurgery (P < 0.01), while the levels of IL4 and IL-10 decreased slightly, and the non-tumor protein lysates induced no obvious changes in the number of IFN-gamma T cells. The cytolytic activity of cytotoxic T lymphocytes against human prostate cancer cells LNCaP was markedly increased, but not that against renal cancer cells GRC-1. One case of recurrence was found during the 3-6 months follow-up.
  
  
  CONCLUSIONS
  Percutaneous cryoablation for prostate cancer could induce a tumor-specific immune response.
authors.affiliation: Department of Interventional Therapy, Cancer Hospital, Tianjin Medical University, Tianjin 300060, China. dr.sitg@yahoo.com.cn
authors.forename: Tong-Guo
authors.initials: TG
authors.lastname: Si
authors.forename: Zhi
authors.initials: Z
authors.lastname: Guo
authors.forename: Hai-Tao
authors.initials: HT
authors.lastname: Wang
authors.forename: Yan-Ping
authors.initials: YP
authors.lastname: Han
authors.forename: Xi-Shan
authors.initials: XS
authors.lastname: Hao
mesh_terms: D000368:Aged; D003452:Cryosurgery; D006801:Humans; D007371:Interferon-gamma / Q000097:blood; D016753:Interleukin-10 / Q000097:blood; D015847:Interleukin-4 / Q000097:blood; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D015847:Interleukin-4; D007371:Interferon-gamma